• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
【24h】

TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.

机译：TNF-α拮抗剂和指甲牛皮癣：一项针对成年牛皮癣患者的开放式，为期24周的前瞻性队列研究。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Treatment of nail psoriasis can be challenging and unsatisfactory. The aim of this study was to compare the efficacy of three different anti-TNF-α agents on nail psoriasis in patients affected by psoriasis.Seventy-two patients with nail psoriasis were evaluated in this open, 24 weeks, prospective study. Patients were enrolled in three groups of treatment: adalimumab, etanercept or infliximab. Severity of nail psoriasis was assessed by the Nail Psoriasis Severity Index (NAPSI) at baseline, week 14, and 24.Sixty patients were included in the study. The mean NAPSI was 33.77. In the adalimumab group, the mean NAPSI score was 33.1 (± 14.9) at baseline, 21 (± 8.91) at week 14 and 11.4 (± 4.6) at week 24 (p < 0.0002). In the etanercept group, the mean NAPSI was 34.8 (± 12.38) at baseline, 23.6 (± 10.43) at week 14, and 10.6 (± 5.25) at week 24 (p < 0.0016). In the infliximab group, the mean NAPSI was 33.3 (± 9.76) at baseline, 14.9 (± 4.20) at week 14 (p < 0.001) and 3.1 (± 3.27) at week 24 (p < 0.00001). At week 14 efficacy was higher in infliximab group compared to adalimumab and etanercept groups (p < 0.05).Among the three agents, in the infliximab group a significant improvement in nail psoriasis was observed as early as week 14 of therapy whereas in the adalimumab and etanercept groups at week 24.
机译：指甲牛皮癣的治疗可能具有挑战性并且不能令人满意。这项研究的目的是比较三种不同的抗TNF-α药物对银屑病患者的指甲牛皮癣的疗效。在这项为期24周的开放性前瞻性研究中，对73例指甲牛皮癣患者进行了评估。患者分为三组治疗：阿达木单抗，依那西普或英夫利昔单抗。通过基线，第14周和第24周的指甲牛皮癣严重程度指数（NAPSI）评估指甲牛皮癣的严重程度。该研究纳入了60名患者。平均NAPSI为33.77。阿达木单抗组的平均NAPSI评分在基线时为33.1（±14.9），在第14周时为21（±8.91），在第24周时为11.4（±4.6）（p <0.0002）。在依那西普组中，平均NAPSI在基线时为34.8（±12.38），在第14周时为23.6（±10.43），在第24周时为10.6（±5.25）（p <0.0016）。在英夫利昔单抗组中，基线时的平均NAPSI为33.3（±9.76），第14周时的平均NAPSI为14.9（±4.20）（p <0.001），第24周时的平均NAPSI为3.1（±3.27）（p <0.00001）。与阿达木单抗和依那西普组相比，英夫利昔单抗组在第14周的疗效更高（p <0.05）。在这三种药物中，英夫利昔单抗组最早在治疗的第14周观察到指甲牛皮癣的明显改善，而阿达木单抗和依那西普依那西普组在第24周。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号